Skip to content


  • Meeting abstract
  • Open Access

Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response

  • 1 and
  • 1
Arthritis Res Ther20035 (Suppl 1) :49

  • Received: 14 January 2003
  • Published:


  • Public Health
  • Rheumatoid Arthritis
  • Arthritis
  • Tumor Necrosis
  • Tumor Necrosis Factor


Infliximab is an anti-tumor-necrosis-factor (anti-TNF) antibody used for the treatment of rheumatoid arthritis.


To clarify heterogeneity in patient response, a bioassay was established to measure functional circulating tumor necrosis factor (TNF).


Culture of TNF activated synoviocytes with plasma samples before and after infliximab treatment showed an increased production of IL-6 that was strongly reduced by treatment. This pattern was associated with a good clinical response, and bioactive TNF levels detected with this bioassay were correlated with TNF levels measured by ELISA. This was not observed in patients with a poor response. The functional circulating bioactive TNF was significantly (P < 0.001) more elevated in subset with a good biological response than bad responders. No correlation was observed with levels of soluble receptors.


This result suggests the importance of systemic bioactive TNF in such response.

Authors’ Affiliations

Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Hérriot, Lyon, France


© The Author(s) 2003